Characteristics of patients at AML diagnosis
| Characteristic . | DDX41MutGL AML . | DDX41WT AML, CT . | ||
|---|---|---|---|---|
| . | All . | RL . | CT . | . |
| No. of patients | 191 | 105 | 86 | 1604 |
| Male | 144 (75%) | 80 (76%) | 64 (74%) | 866 (54%) |
| Age, y | 66 (59-70) | 66 (59-70) | 66 (61-69) | 64 (54-69) |
| Hb, g/dL | 10.4 (8.6-11.9) | 10.3 (8.3-11.9) | 10.7 (9.6-12.0) | 9.8 (8.6-10.8) |
| WBC, ×109/L | 1.99 (1.46-2.60) | 1.90 (1.42-2.45) | 2.00 (1.50-2.70) | 7.9 (2.5-31.1) |
| ANC, ×109/L | 0.62 (0.26-0.94) | 0.62 (0.27-0.96) | 0.60 (0.30-0.90) | ND |
| Platelets, ×109/L | 64 (39-110) | 63 (37-85) | 82 (42-171) | 85 (42-174) |
| BM blasts, % | 33 (24-47) | 30 (23-47) | 37 (28-47) | 58 (35-80) |
| Trial, n (% in trial) | ||||
| ALFA-0701 | NA | NA | 10 (5.4%) | 176 (94.6%) |
| ALFA-0702 | NA | NA | 15 (2.7%) | 531 (97.3%) |
| ALFA-1200 | NA | NA | 23 (5.3%) | 408 (94.7%) |
| ALFA-1401 | NA | NA | 15 (7.6%) | 182 (92.4%) |
| LAM-SA 2007 | NA | NA | 23 (6.9%) | 307 (93.1%) |
| FAB classification | ||||
| Available | 70 | 47 | 23 | ND |
| M0 | 7 (10%) | 5 (11%) | 2 (9%) | ND |
| M1 | 17 (25%) | 14 (30%) | 3 (13%) | ND |
| M2 | 42 (60%) | 24 (51%) | 18 (78%) | ND |
| M4 | 2 (3%) | 2 (4%) | 0 | ND |
| M5 | 1 (1%) | 1 (2%) | 0 | ND |
| M6 | 1 (1%) | 1 (2%) | 0 | ND |
| Cytogenetics | ||||
| Available | 156 | 80 | 76 | 1500 |
| Normal | 117 (75%) | 59 (74%) | 58 (77%) | 860 (57%) |
| Complex | 1 (1%) | 1 (1%) | 0 | 139 (9%) |
| Trisomy 8 | 8 (5%) | 6 (8%) | 2 (3%) | 158 (11%) |
| Monosomy 5/del(5q) | 3 (2%) | 2 (3%) | 1 (1%) | 77 (5%) |
| Monosomy 7 | 2 (1%) | 1 (1%) | 1 (1%) | 65 (4%) |
| Monosomy 17/del(17p) | 0 | 0 | 0 | 58 (4%) |
| ELN-2017 risk | ||||
| Available | 160 | 81 | 79 | 1545 |
| Favorable | 9 (5%) | 6 (7%) | 3 (4%) | 549 (36%) |
| Intermediate | 105 (66%) | 51 (63%) | 54 (68%) | 427 (28%) |
| Adverse | 46 (29%) | 24 (30%) | 22 (28%) | 569 (37%) |
| Characteristic . | DDX41MutGL AML . | DDX41WT AML, CT . | ||
|---|---|---|---|---|
| . | All . | RL . | CT . | . |
| No. of patients | 191 | 105 | 86 | 1604 |
| Male | 144 (75%) | 80 (76%) | 64 (74%) | 866 (54%) |
| Age, y | 66 (59-70) | 66 (59-70) | 66 (61-69) | 64 (54-69) |
| Hb, g/dL | 10.4 (8.6-11.9) | 10.3 (8.3-11.9) | 10.7 (9.6-12.0) | 9.8 (8.6-10.8) |
| WBC, ×109/L | 1.99 (1.46-2.60) | 1.90 (1.42-2.45) | 2.00 (1.50-2.70) | 7.9 (2.5-31.1) |
| ANC, ×109/L | 0.62 (0.26-0.94) | 0.62 (0.27-0.96) | 0.60 (0.30-0.90) | ND |
| Platelets, ×109/L | 64 (39-110) | 63 (37-85) | 82 (42-171) | 85 (42-174) |
| BM blasts, % | 33 (24-47) | 30 (23-47) | 37 (28-47) | 58 (35-80) |
| Trial, n (% in trial) | ||||
| ALFA-0701 | NA | NA | 10 (5.4%) | 176 (94.6%) |
| ALFA-0702 | NA | NA | 15 (2.7%) | 531 (97.3%) |
| ALFA-1200 | NA | NA | 23 (5.3%) | 408 (94.7%) |
| ALFA-1401 | NA | NA | 15 (7.6%) | 182 (92.4%) |
| LAM-SA 2007 | NA | NA | 23 (6.9%) | 307 (93.1%) |
| FAB classification | ||||
| Available | 70 | 47 | 23 | ND |
| M0 | 7 (10%) | 5 (11%) | 2 (9%) | ND |
| M1 | 17 (25%) | 14 (30%) | 3 (13%) | ND |
| M2 | 42 (60%) | 24 (51%) | 18 (78%) | ND |
| M4 | 2 (3%) | 2 (4%) | 0 | ND |
| M5 | 1 (1%) | 1 (2%) | 0 | ND |
| M6 | 1 (1%) | 1 (2%) | 0 | ND |
| Cytogenetics | ||||
| Available | 156 | 80 | 76 | 1500 |
| Normal | 117 (75%) | 59 (74%) | 58 (77%) | 860 (57%) |
| Complex | 1 (1%) | 1 (1%) | 0 | 139 (9%) |
| Trisomy 8 | 8 (5%) | 6 (8%) | 2 (3%) | 158 (11%) |
| Monosomy 5/del(5q) | 3 (2%) | 2 (3%) | 1 (1%) | 77 (5%) |
| Monosomy 7 | 2 (1%) | 1 (1%) | 1 (1%) | 65 (4%) |
| Monosomy 17/del(17p) | 0 | 0 | 0 | 58 (4%) |
| ELN-2017 risk | ||||
| Available | 160 | 81 | 79 | 1545 |
| Favorable | 9 (5%) | 6 (7%) | 3 (4%) | 549 (36%) |
| Intermediate | 105 (66%) | 51 (63%) | 54 (68%) | 427 (28%) |
| Adverse | 46 (29%) | 24 (30%) | 22 (28%) | 569 (37%) |
Data are expressed as median (IQR) unless otherwise indicated.
ANC, absolute neutrophil count; BM, bone marrow; FAB, French-American-British; Hb, hemoglobin; NA, not applicable; ND, not defined.